Mabion S.A. Total Assets
Mabion S.A. total assets. Based on the latest financial reports, Mabion S.A. (MAB) holds total assets worth zł102.20 Million PLN (≈ $28.13 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Mabion S.A. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Mabion S.A. (2009–2025)
Total assets of Mabion S.A. from 2009 to 2025. This chart illustrates how Mabion S.A.'s total assets have evolved over time, based on quarterly financial data. See Mabion S.A. stock quote for real-time trading data and today's change.
Mabion S.A. - Asset Composition Analysis
Mabion S.A. Total Assets Breakdown (December 2025)
Mabion S.A. total assets breakdown as of December 2025. Mabion S.A.'s total assets of zł102.20 Million consist of 11.6% current assets and 88.4% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 5.8% |
| Accounts Receivable | zł3.17 Million | 2.9% |
| Inventory | zł1.41 Million | 1.3% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł159.00K | 0.1% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Mabion S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MAB working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mabion S.A.'s current assets represent 11.6% of total assets in 2025, a decrease from 59.4% in 2009.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2025, up from 1.5% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 2.9% of total assets.
Mabion S.A. Competitors by Total Assets
Key competitors of Mabion S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Mabion S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.32 | 0.45 | 0.95 |
| Quick Ratio | 0.18 | 0.39 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł-31.82 Million | zł-21.24 Million | zł-5.76 Million |
Mabion S.A. - Advanced Valuation Insights
This section examines the relationship between Mabion S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.25 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -30.8% |
| Total Assets | zł110.43 Million |
| Market Capitalization | $34.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mabion S.A.'s assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mabion S.A.'s assets decreased by 30.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mabion S.A. (2009–2025)
The table below shows the annual total assets of Mabion S.A. from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł110.43 Million ≈ $30.39 Million |
-30.75% |
| 2024-12-31 | zł159.47 Million ≈ $43.89 Million |
-23.42% |
| 2023-12-31 | zł208.25 Million ≈ $57.31 Million |
+11.86% |
| 2022-12-31 | zł186.18 Million ≈ $51.24 Million |
+1.05% |
| 2021-12-31 | zł184.24 Million ≈ $50.70 Million |
+135.23% |
| 2020-12-31 | zł78.32 Million ≈ $21.56 Million |
-31.02% |
| 2019-12-31 | zł113.55 Million ≈ $31.25 Million |
-21.54% |
| 2018-12-31 | zł144.72 Million ≈ $39.83 Million |
+75.53% |
| 2017-12-31 | zł82.44 Million ≈ $22.69 Million |
-9.65% |
| 2016-12-31 | zł91.25 Million ≈ $25.11 Million |
-52.86% |
| 2015-12-31 | zł193.55 Million ≈ $53.27 Million |
-86.93% |
| 2014-12-31 | zł1.48 Billion ≈ $407.64 Million |
+96.26% |
| 2013-12-31 | zł754.68 Million ≈ $207.70 Million |
-80.97% |
| 2012-12-31 | zł3.97 Billion ≈ $1.09 Billion |
+14620.07% |
| 2011-12-31 | zł26.94 Million ≈ $7.41 Million |
+14.95% |
| 2010-12-31 | zł23.44 Million ≈ $6.45 Million |
+6632.39% |
| 2009-12-31 | zł348.15K ≈ $95.82K |
-- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartere… Read more